I am responsible for identifying and developing collaborations and partnerships that complement and support the growth of Calico's internal research and development programs.
Before Calico, I was responsible for portfolio strategy across business development, finance and the project teams at Ovid Therapeutics. In this role, I led search and evaluation activities, supported the development of a partnership with Takeda Pharmaceuticals to bring a Phase 2 CNS compound into the pipeline and was a key member of the team that led the initial public offering. Prior to Ovid, I held positions in both non-profit at the Alzheimer’s Drug Discovery Foundation (ADDF) and on Wall Street. At the ADDF, I led seed investments and the development of public-private partnerships to support the translation of novel drug targets for neurodegenerative disease. As a research analyst on Wall Street, I provided investment recommendations on small and large-cap biotech at a healthcare-focused investment bank.
I trained in cell and molecular biology and completed my postdoctoral research at Icahn School of Medicine at Mount Sinai on the neurobiology of Alzheimer's disease.